Acamprosate for the treatment of alcohol use disorder may be safer than baclofen in patients with cirrhosis

被引：0
|
作者：
Tyson, Luke D. [1 ,2 ]
Cheng, Alexandra [2 ]
Kelleher, Charles [2 ]
Strathie, Kirstin [2 ]
Lovendoski, James [2 ]
Habtemariam, Zebib [2 ]
Lewis, Heather [2 ]
机构：
[1] Imperial Coll London, Dept Metab Digest & Reprod, London, England
[2] Imperial Coll Healthcare NHS Trust, Dept Hepatol, London, England
来源：
JOURNAL OF HEPATOLOGY | 2021年 / 75卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
PO-607
引用
收藏
页码：S314 / S314
页数：1
相关论文
共 50 条
  • [21] SEX AS A POTENTIAL MODERATOR FOR BACLOFEN RESPONSE IN THE TREATMENT OF ALCOHOL USE DISORDER
    Morley, K. C.
    Logge, W.
    Louie, E.
    Hurzeler, T.
    Baillie, A.
    Haber, P.
    ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 2022, 46 : 169A - 169A
  • [22] Role of Acamprosate and Baclofen as Anti-craving Agents in Alcohol Use Disorder: A 12-Week Prospective Study
    Sharma, Akhilesh K.
    Rikhari, Praveen
    Shukla, Alok K.
    Rikhari, Pragya
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (04)
  • [23] The Diffusion of Acamprosate for the Treatment of Alcohol Use Disorder: Results From a National Longitudinal Study
    Knudsen, Hannah K.
    Roman, Paul M.
    JOURNAL OF SUBSTANCE ABUSE TREATMENT, 2016, 62 : 62 - 67
  • [24] Metabolomic biomarkers in response to acamprosate in alcohol use disorder subjects
    Choi, D. S.
    ALCOHOL-CLINICAL AND EXPERIMENTAL RESEARCH, 2023, 47 : 117 - 118
  • [25] ASSOCIATION OF ACAMPROSATE VS GABAPENTINOIDS AND LIVER DISEASE PROGRESSION IN PATIENTS WITH ALCOHOL USE DISORDER
    Shah, Raj
    Zelneronok, Kirsten
    Henriquez, Richard
    Mansi, Ishak
    GASTROENTEROLOGY, 2024, 166 (05) : S1557 - S1557
  • [26] Neurometabolite Levels in Alcohol Use Disorder Patients During Baclofen Treatment and Prediction of Relapse to Heavy Drinking
    Morley, Kirsten C.
    Lagopoulos, Jim
    Logge, Warren
    Chitty, Kate
    Baillie, Andrew
    Haber, Paul S.
    FRONTIERS IN PSYCHIATRY, 2018, 9
  • [27] Gender Disparities in Alcohol Use Disorder Treatment Among Privately Insured Patients with Alcohol-Associated Cirrhosis
    Mellinger, Jessica L.
    Fernandez, Anne
    Shedden, Kerby
    Winder, G. Scott
    Fontana, Robert J.
    Volk, Michael L.
    Blow, Frederic C.
    Lok, Anna S. F.
    ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 2019, 43 (02) : 334 - 341
  • [28] Baclofen for alcohol use disorder: Mechanisms, results and safety
    Dehanov, S.
    Oliveira, C.
    Ferreira, T.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2019, 29 : S316 - S316
  • [29] BACLOFEN FOR TREATMENT OF ALCOHOL USE DISORDER: SECONDARY ANALYSES AND IMPLICATIONS OF THE AUSTRALIAN BACALD TRIAL
    Morley, Kirsten
    Luquin, Natasha
    Lagopoulos, Jim
    Logge, Warren
    Baillie, Andrew
    Haber, Paul S.
    DRUG AND ALCOHOL REVIEW, 2019, 38 : S75 - S75
  • [30] INITIATION OF NALTREXONE IS ASSOCIATED WITH LOWER RATES OF SBP AND MORTALITY THAN ACAMPROSATE IN PATIENTS WITH DECOMPENSATED ALCOHOL-ASSOCIATED CIRRHOSIS
    Jahagirdar, Vinay
    Cooper, Katherine
    Devuni, Deepika
    HEPATOLOGY, 2024, 80
12345